Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 49.98M P/E - EPS this Y -80.60% Ern Qtrly Grth -
Income -8.12M Forward P/E -1.09 EPS next Y -20.90% 50D Avg Chg 23.00%
Sales 57.31M PEG -0.17 EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book N/A EPS next 5Y 3.20% 52W High Chg -37.00%
Recommedations 2.00 Quick Ratio 0.68 Shares Outstanding 6.58M 52W Low Chg 100.00%
Insider Own 3.96% ROA -9.84% Shares Float 3.90M Beta 1.10
Inst Own 58.79% ROE - Shares Shorted/Prior 205.63K/27.30K Price 0.62
Gross Margin 14.71% Profit Margin -14.18% Avg. Volume 207,909 Target Price 16.50
Oper. Margin -76.55% Earnings Date May 13 Volume 233,401 Change 4.73%
About Molecular Templates, Inc.

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Molecular Templates, Inc. News
04/09/24 Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
03/29/24 Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
03/28/24 Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
03/04/24 Molecular Templates, Inc. Provides Interim Update
02/08/24 Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
11/13/23 Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
11/02/23 Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
11/01/23 Molecular Templates to Participate in Upcoming Investor Conferences
09/28/23 Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
08/25/23 Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
08/11/23 Molecular Templates Announces 1-for-15 Reverse Stock Split
08/10/23 Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
08/02/23 Molecular Templates Announces Executive Leadership Changes
07/13/23 Molecular Templates Announces Up to $40 Million Private Placement Offering
06/16/23 Molecular Templates Announces Debt Payoff and Restructuring
06/01/23 Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
05/26/23 Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
05/15/23 Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
MTEM Chatroom

User Image onefryshy Posted - 3 days ago

$MTEM waiting for another shoe to drop. If it cost $20,000 per cancer patient for molecular templates to test, they need more money.

User Image a36er Posted - 04/25/24

$MTEM Never really know if S3s are gonna be good or bad....

User Image DonCorleone77 Posted - 04/25/24

$MTEM Molecular Templates files to sell 11.01M shares of common stock for holders

User Image onefryshy Posted - 04/25/24

$MTEM it appears from the Bristol-Myers news that molecular templates was not singled out as a particular study to be dropped there were a number of partnerships which were canceled in order to focus on their recent purchases and save money.

User Image pretrader Posted - 04/22/24

$MTEM @Humble_Amateur @onefryshy what happened? I step away from looking at $MTEM and my $7.04 average is making me said. Ofc I don't have more cash in that pretax to average down. So when are we getting to $21 to satisfy that whatever condition for additional funding it was? Saw MTEM did layoffs. @Humble_Amateur did you add low?

User Image sblanch Posted - 04/18/24

$MTEM At 1.50$, it is 10 cents before reverse split. 🤨

User Image Tundra3 Posted - 04/15/24

$MTEM Out at $1.88. Good luck.

User Image a36er Posted - 04/14/24

$MTEM Anyone see the 8k published on 4/12? Further reduction in workforce (30%) and CMO is out on 4/30. Don't know what to make of Voi departing on 4/30 since the CMO position has been a revolving door. I still see MTEM as being acquired....probably even more so now. just not at a "good" price for current equity holders.

User Image Tundra3 Posted - 04/13/24

$MTEM Garbage

User Image Tundra3 Posted - 04/12/24

$MTEM Watchers dropping 🙄 Don’t blame ‘em!

User Image Tundra3 Posted - 04/12/24

$MTEM

User Image Tundra3 Posted - 04/11/24

$MTEM Is this some life? Molecular Templates shares are trading higher after the company announced that it will present interim data from its MT-6402 Phase I study in patients with PD-L1+ solid tumors at the 2024 AACR annual meeting.

User Image Tundra3 Posted - 04/11/24

$MTEM guessing the company doesn’t care that their stock is at an all-time low this week?

User Image Tundra3 Posted - 04/11/24

$MTEM

User Image momlaurie Posted - 04/10/24

$MTEM

User Image Tundra3 Posted - 04/09/24

$MTEM Well that’s not happening

User Image momlaurie Posted - 04/09/24

$MTEM

User Image momlaurie Posted - 04/09/24

$MTEM

User Image hi_tech_low_life Posted - 04/09/24

What's Going On With Molecular Templates Stock? $MTEM https://www.benzinga.com/news/24/04/38168069/whats-going-on-with-molecular-templates-stock

User Image Tundra3 Posted - 04/09/24

$MTEM what’s with the $2.60 warrants?

User Image cfvk Posted - 04/09/24

$MTEM wish i had sold premarket, oops. well at least i'm even.

User Image momlaurie Posted - 04/09/24

$MTEM

User Image Tundra3 Posted - 04/09/24

$MTEM How does news release and then this drops to the lowest price it’s been in a year?? What the actual F???

User Image ToldUsooOOOO Posted - 04/09/24

$MTEM hmm nothing warranting this drop. In

User Image Beardiediediedie Posted - 04/09/24

$MTEM scam

User Image CyprusAgency Posted - 04/09/24

$MTEM $MYMD

User Image Tundra3 Posted - 04/09/24

$MTEM Now it’s dead

User Image ANTHONYMOMO Posted - 04/09/24

$MTEM under accumulation new lase

User Image gerbey Posted - 04/09/24

$MTEM $MYMD 👀👀

User Image ANTHONYMOMO Posted - 04/09/24

$MTEM I hope you grabbed a few

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BIOTECH TARGET N V Director Director Jul 17 Buy 0.470 4,255,319 2,000,000 15,447,322 07/19/23
Kim Jason S. See remarks See remarks Jul 07 Option 0.71 12,089 8,583 95,493 07/11/22
LALANDE KEVIN M. Director Director Jun 13 Buy 0.89 222,000 197,580 222,000 06/21/22
SHV Management Services, LLC 10% Owner 10% Owner Jun 13 Buy 0.89 222,000 197,580 222,000 06/21/22
McLennan Sean See remarks See remarks Jun 16 Buy 0.8159 30,000 24,477 30,000 06/21/22
BIOTECH TARGET N V 10% Owner 10% Owner May 16 Buy 1.181 200,000 236,200 11,192,003 05/18/22
Poma Eric E See remarks See remarks Apr 27 Option 0.71 34,156 24,251 277,615 04/29/22
BIOTECH TARGET N V 10% Owner 10% Owner Jan 06 Buy 4.0359 200,000 807,180 10,992,003 01/10/22